Pfizer Inc.
Azalactam Compounds as HPK1 Inhibitors

Abstract:

This invention relates to compounds of general Formula (I) ##STR00001## and pharmaceutically acceptable salts thereof, in which R.sup.1, R.sup.1a, R.sup.2, R.sup.3, R.sup.4, and (R.sup.5).sub.a are as defined herein, to pharmaceutical compositions comprising such compounds and pharmaceutically acceptable salts thereof, and to methods of using such compounds, pharmaceutically acceptable salts and compositions for the treatment of abnormal cell growth, including cancer.